David M Thomas,,, Fracp

List of Publications by Year
in descending order

188 papers	14,181 citations	30070 54 h-index	21540 114 g-index

196 all docs	196 docs citations	196 times ranked	20984 citing authors

#	Article	IF	Citations
1	The Hippo pathway and human cancer. Nature Reviews Cancer, 2013, 13, 246-257.	28.4	1,479
2	Translational biology of osteosarcoma. Nature Reviews Cancer, 2014, 14, 722-735.	28.4	939
3	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncology, The, 2010, 11, 275-280.	10.7	607
4	The distinctive biology of cancer in adolescents and young adults. Nature Reviews Cancer, 2008, 8, 288-298.	28.4	540
5	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncology, The, 2013, 14, 901-908.	10.7	487
6	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. Journal of Clinical Oncology, 1999, 17, 3110-3116.	1.6	393
7	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone. Clinical Cancer Research, 2012, 18, 4415-4424.	7.0	372
8	The Retinoblastoma Protein Acts as a Transcriptional Coactivator Required for Osteogenic Differentiation. Molecular Cell, 2001, 8, 303-316.	9.7	343
9	FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor. Cancer Discovery, 2012, 2, 1118-1133.	9.4	297
10	Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature, 1987, 326, 697-698.	27.8	276
11	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	13.7	273
12	Molecular Pathogenesis of Osteosarcoma. DNA and Cell Biology, 2007, 26, 1-18.	1.9	269
13	Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 2016, 6, 7.	2.8	266
14	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer, 2006, 6, 295.	2.6	254
15	Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. Journal of Clinical Investigation, 2009, 119, 837-851.	8.2	244
16	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	4.1	222
17	Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 2014, 11, 260-271.	27.6	218
18	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 2015, 21, 2029-2037.	7.0	209

#	Article	IF	Citations
19	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Medical Genomics, 2014, 7, 23.	1.5	200
20	Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to Overcome. Journal of Clinical Oncology, 2010, 28, 4850-4857.	1.6	199
21	Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. Journal of Cell Biology, 2004, 167, 925-934.	5.2	198
22	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nature Medicine, 2020, 26, 1742-1753.	30.7	185
23	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
24	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 2303-2312.	1.6	161
25	The Architecture and Evolution of Cancer Neochromosomes. Cancer Cell, 2014, 26, 653-667.	16.8	161
26	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncology, The, 2016, 17, 1261-1271.	10.7	161
27	Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation. Journal of Bone and Mineral Research, 1999, 14, 342-350.	2.8	156
28	RECKâ€”a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer and Metastasis Reviews, 2007, 26, 675-683.	5.9	151
29	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
30	Liposarcoma: Molecular Genetics and Therapeutics. Sarcoma, 2011, 2011, 1-13.	1.3	146
31	Giant cell tumour of bone. Current Opinion in Oncology, 2009, 21, 338-344.	2.4	143
32	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
33	The relationship between unmet needs and distress amongst young people with cancer. Supportive Care in Cancer, 2012, 20, 75-85.	2.2	130
34	IFN-Î³ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications, 2017, 8, 14607.	12.8	125
35	Delivering precision oncology to patients with cancer. Nature Medicine, 2022, 28, 658-665.	30.7	125
36	Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor ÎºB. American Journal of Pathology, 2005, 167, 117-128.	3.8	124

#	Article	IF	Citations
37	Diagnosis of fusion genes using targeted RNA sequencing. Nature Communications, 2019, 10, 1388.	12.8	122
38	Adolescent and Young Adult Oncology: An Emerging Field. Journal of Clinical Oncology, 2010, 28, 4781-4782.	1.6	114
39	Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis. Clinical Cancer Research, 2011, 17, 416-426.	7.0	106
40	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. OncoImmunology, 2020, 9, 1747340.	4.6	101
41	Role of the Retinoblastoma Protein in Differentiation and Senescence. Cancer Biology and Therapy, 2003, 2, 124-130.	3.4	96
42	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96
43	Massivelyâ€parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. Journal of Pathology, 2013, 231, 413-423.	4.5	94
44	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
45	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
46	PPARÎ³-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer, 2006, 6, 53.	2.6	83
47	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science, 2020, 368, 1127-1131.	12.6	83
48	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical Sarcoma Research, 2016, 6, 15.	2.3	80
49	An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development. Cancer Research, 2005, 65, 9633-9636.	0.9	75
50	RANKL, denosumab, and giant cell tumor of bone. Current Opinion in Oncology, 2012, 24, 397-403.	2.4	74
51	Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18402-18407.	7.1	63
52	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. Journal of Clinical Oncology, 2011, 29, 2781-2786.	1.6	61
53	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology, 2019, 32, 1772-1785.	5.5	61
54	A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochemical Journal, 2005, 390, 427-436.	3.7	60

#	Article	IF	Citations
55	Epigenetic modifications in osteogenic differentiation and transformation. Journal of Cellular Biochemistry, 2006, 98, 757-769.	2.6	57
56	HES1 Cooperates With pRb to Activate RUNX2-Dependent Transcription. Journal of Bone and Mineral Research, 2006, 21, 921-933.	2.8	55
57	Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. Journal of Clinical Investigation, 2013, 123, 5351-5360.	8.2	54
58	High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort. PLoS ONE, 2013, 8, e69026.	2.5	51
59	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
60	Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma. Journal of Molecular Diagnostics, 2011, 13, 289-296.	2.8	49
61	Locally Aggressive Connective Tissue Tumors. Journal of Clinical Oncology, 2018, 36, 202-209.	1.6	48
62	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nature Communications, 2020, 11, 435.	12.8	47
63	Dendritic cell immunotherapy for stage IV melanoma. Melanoma Research, 2007, 17, 316-322.	1.2	46
64	The STATs in cell stress-type responses. Cell Communication and Signaling, 2004, 2, 8.	6.5	41
65	Parathyroid Hormoneâ€“Related Protein Protects against Mammary Tumor Emergence and Is Associated with Monocyte Infiltration in Ductal Carcinoma In situ. Cancer Research, 2009, 69, 7473-7479.	0.9	41
66	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Review of Anticancer Therapy, 2009, 9, 1145-1157.	2.4	41
67	Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer. Genome Research, 2018, 28, 726-738.	5.5	41
68	Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?. Familial Cancer, 2017, 16, 423-432.	1.9	39
69	Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 2019, 16, 386-396.	27.6	39
70	Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. , 2012, 136, 153-168.		36
71	ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Medicine, 2021, 13, 32.	8.2	36
72	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signalâ€seeking studies of targeted therapies for rare and neglected cancers. Medical Journal of Australia, 2018, 209, 354-355.	1.7	35

#	Article	IF	Citations
73	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. Journal of Clinical Oncology, 2012, 30, 2334-2339.	1.6	34
74	Surveillance recommendations for patients with germline TP53 mutations. Current Opinion in Oncology, 2015, 27, 332-337.	2.4	33
75	Safety of denosumab in giant-cell tumour of bone. Lancet Oncology, The, 2010, 11, 815.	10.7	32
76	BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1190-1203.	6.3	32
77	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 2021, 35, 3245-3256.	7.2	32
78	Genderâ€specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. International Journal of Cancer, 2009, 125, 426-431.	5.1	31
79	Chemical Genetics of Rapamycin-Insensitive TORC2 in S.Âcerevisiae. Cell Reports, 2013, 5, 1725-1736.	6.4	31
80	Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. Cancer Research, 2017, 77, 4279-4292.	0.9	31
81	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
82	Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma, 2011, 2011, 1-17.	1.3	30
83	Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e562-e570.	10.7	30
84	Next-Generation Sequence Analysis of Cancer Xenograft Models. PLoS ONE, 2013, 8, e74432.	2.5	30
85	Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24.	2.2	30
86	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 2017, 107, 22-35.	2.0	30
87	Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma, 2013, 2013, 1-11.	1.3	29
88	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. European Journal of Human Genetics, 2019, 27, 308-316.	2.8	28
89	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery, 2019, 9, 1511-1519.	9.4	26
90	Etiologic, environmental and inherited risk factors in sarcomas. Journal of Surgical Oncology, 2015, 111, 490-495.	1.7	25

#	Article	IF	Citations
91	Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling. Cancer Research, 2014, 74, 921-931.	0.9	24
92	RECK in osteosarcoma. Cancer, 2011, 117, 3517-3528.	4.1	22
93	Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Research, 2020, 80, 354-360.	0.9	22
94	Patient perspectives on molecular tumor profiling: â€œWhy wouldnâ€™t you?â€. BMC Cancer, 2019, 19, 753.	2.6	21
95	A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Human Mutation, 2019, 40, 788-800.	2.5	21
96	Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biology, 2021, 22, 109.	8.8	20
97	Altered responsiveness of proximal tubule fluid reabsorption of peritubular angiotensin II in spontaneously hypertensive rats. Journal of Hypertension, 1990, 8, 407-410.	0.5	19
98	Multidisciplinary approach to diagnosis and management of osteosarcoma â€“ a review of the St Vincent's Hospital experience. International Seminars in Surgical Oncology, 2006, 3, 38.	1.1	19
99	Wnts, bone and cancer. Journal of Pathology, 2010, 220, 1-4.	4.5	17
100	Clinical implications of genomics for cancer risk genetics. Lancet Oncology, The, 2015, 16, e303-e308.	10.7	17
101	STI-571 inhibits in vitro angiogenesis. Biochemical and Biophysical Research Communications, 2003, 310, 135-142.	2.1	16
102	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer, 2011, 11, 93.	2.6	16
103	Cancer patientsâ€™ views and understanding of genome sequencing: a qualitative study. Journal of Medical Genetics, 2020, 57, 671-676.	3.2	16
104	Sarcoma in the Young Adult Population: An International View. Seminars in Oncology, 2009, 36, 227-236.	2.2	15
105	A role for Î±V integrin subunit in TGF-Î²-stimulated osteoclastogenesis. Biochemical and Biophysical Research Communications, 2003, 307, 1051-1058.	2.1	14
106	Multiomics medicine in oncology: assessing effectiveness, costâ€“effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics, 2013, 14, 1405-1417.	1.3	14
107	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24â€“25, 2015. Workshop Report. Clinical Sarcoma Research, 2016, 6, 3.	2.3	14
108	Estimating TP53 Mutation Carrier Probability in Families with Liâ€“Fraumeni Syndrome Using LFSPRO. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 837-844.	2.5	14

#	Article	IF	Citations
109	Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1735.	7.1	14
110	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. BMC Cancer, 2018, 18, 454.	2.6	14
111	Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: â€˜Another piece of the pieâ€™. Journal of Genetic Counseling, 2021, 30, 849-860.	1.6	13
112	Other Targetable Sarcomas. Seminars in Oncology, 2009, 36, 358-371.	2.2	12
113	Cancerâ€associated neochromosomes: a novel mechanism of oncogenesis. BioEssays, 2009, 31, 1191-1200.	2.5	12
114	Atypical Ewing sarcoma breakpoint region 1 fluorescence inâ€situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 2016, 69, 1000-1011.	2.9	12
115	In vitro and inâ€‰vivo drug screens of tumor cells identify novel therapies for highâ€risk child cancer. EMBO Molecular Medicine, 2022, 14, e14608.	6.9	12
116	Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. OncoImmunology, 2012, 1, 1313-1322.	4.6	11
117	A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 67-78.	2.8	11
118	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 38-47.	1.1	11
119	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. Patient Education and Counseling, 2021, 104, 944-952.	2.2	11
120	The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. BMC Cancer, 2013, 13, 585.	2.6	10
121	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. BMC Cancer, 2018, 18, 389.	2.6	10
122	Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks. Journal of Telemedicine and Telecare, 2023, 29, 641-647.	2.7	10
123	Towards social connection for young people with cancer. , 2008, , .		9
124	Novel Approaches to Treatment of Leiomyosarcomas. Current Oncology Reports, 2011, 13, 316-322.	4.0	9
125	Stressâ€induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets. BioEssays, 2014, 36, 552-560.	2.5	9
126	Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncology, The, 2015, 16, e190-e194.	10.7	9

#	Article	IF	Citations
127	Timing and context: important considerations in the return of genetic results to research participants. Journal of Community Genetics, 2016, 7, 11-20.	1.2	9
128	â€œCancer 2015â€: A Prospective, Population-Based Cancer Cohortâ€”Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine, 2015, 5, 354-369.	2.5	8
129	The life history of neochromosomes revealed. Molecular and Cellular Oncology, 2015, 2, e1000698.	0.7	8
130	<scp>PD</scp>â€1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. Cancer Reports, 2021, 4, e1327.	1.4	8
131	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. Expert Review of Molecular Diagnostics, 2008, 8, 105-119.	3.1	7
132	Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. Nature Reviews Clinical Oncology, 2012, 9, 431-432.	27.6	7
133	Hereditary and environmental epidemiology of sarcomas. Clinical Sarcoma Research, 2012, 2, 13.	2.3	7
134	The growing problem of benign connective tissue tumours. Lancet Oncology, The, 2015, 16, 879-880.	10.7	7
135	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Journal of Physical Education and Sports Management, 2019, 5, a003764.	1.2	7
136	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. JAMA Network Open, 2020, 3, e204721.	5.9	7
137	Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling. Translational Oncology, 2020, 13, 100799.	3.7	7
138	Germline RET variants underlie a subset of paediatric osteosarcoma. Journal of Medical Genetics, 2021, 58, 20-24.	3.2	7
139	Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precision Oncology, 2021, 5, 1160-1165.	3.0	7
140	Medical Research Council Adjuvant Trial in High-Grade Gliomas. Journal of Clinical Oncology, 2001, 19, 3997-3999.	1.6	6
141	Adolescents and young adults with cancer: The challenge. Palliative and Supportive Care, 2007, 5, 173-174.	1.0	6
142	Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk. Journal of Genetic Counseling, 2018, 27, 1055-1066.	1.6	6
143	Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting. European Journal of Human Genetics, 2022, 30, 930-937.	2.8	6
144	Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma. Skeletal Radiology, 2006, 35, 311-318.	2.0	5

#	Article	IF	Citations
145	Lessons from the deep study of rare tumours. Journal of Pathology, 2011, 224, 306-308.	4.5	5
146	RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma. OncoImmunology, 2014, 3, e27569.	4.6	5
147	Adding the â€˜medicinesâ€™ back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 2015, 80, 929-931.	2.4	5
148	Advanced cancer patient preferences for receiving molecular profiling results. Psycho-Oncology, 2020, 29, 1533-1539.	2.3	5
149	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. Patient Education and Counseling, 2022, 105, 452-459.	2.2	5
150	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. Npj Precision Oncology, 2021, 5, 58.	5.4	5
151	Diagnosis and Management of Hereditary Sarcoma. Recent Results in Cancer Research, 2016, 205, 169-189.	1.8	4
152	Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers. Medical Journal of Australia, 2018, 209, 330-332.	1.7	4
153	Translating genomic risk into an early detection strategy for sarcoma. Genes Chromosomes and Cancer, 2019, 58, 130-136.	2.8	4
154	Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. Patient Education and Counseling, 2022, 105, 2206-2216.	2.2	4
155	Counterpoints in cancer: The somatic mutation theory under attack. BioEssays, 2011, 33, 313-314.	2.5	3
156	International survey of awareness of genetic risk in the clinical sarcoma community. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 133-142.	1.1	3
157	Who should access germline genome sequencing? A mixed methods study of patient views. Clinical Genetics, 2020, 97, 329-337.	2.0	3
158	Disparities in Cancer Care: The Example of Sarcomaâ€”In Search of Solutions for a Global Issue. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 405-411.	3.8	3
159	Malignant cerebral glioma. BMJ: British Medical Journal, 1997, 314, 899-899.	2.3	3
160	Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1212-1217.	4.9	3
161	Optimising the management of soft tissue tumours. Pathology, 2011, 43, 295-301.	0.6	2
162	Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts. BMC Medical Genetics, 2019, 20, 69.	2.1	2

#	Article	IF	Citations
163	The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. Oncotarget, 2021, 12, 2169-2176.	1.8	2
164	Fear of cancer recurrence in patients undergoing germline genome sequencing. Supportive Care in Cancer, 2021, 29, 7289-7297.	2.2	2
165	Value of wholeâ€genome sequencing to Australian cancer patients and their firstâ€degree relatives participating in a genomic sequencing study. Journal of Genetic Counseling, 2022, 31, 96-108.	1.6	2
166	Cancer patient knowledge about and behavioral intentions after germline genome sequencing. Patient Education and Counseling, 2022, 105, 707-718.	2.2	2
167	Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes and Cancer, 2022, 61, 81-93.	2.8	2
168	Psychological predictors of advanced cancer patientsâ€™ preferences for return of results from comprehensive tumor genomic profiling. American Journal of Medical Genetics, Part A, 2022, 188, 725-734.	1.2	2
169	Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. Public Health Genomics, 2022, 25, 70-79.	1.0	2
170	Psychological predictors of cancer patients' and their relativesâ€™ attitudes towards the return of genomic sequencing results. European Journal of Medical Genetics, 2022, 65, 104516.	1.3	2
171	A 3-dimensional digitizer using spherical co-ordinates. Australian Dental Journal, 1988, 33, 138-143.	1.5	1
172	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. Prostate Journal, 2001, 3, 30-35.	0.2	1
173	Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?. Heart Lung and Circulation, 2008, 17, 451-462.	0.4	1
174	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. Drug Discovery Today, 2015, 20, 1429-1432.	6.4	1
175	Sarcoma and germ-line DICER1 mutations â€“ Authorsâ€™ reply. Lancet Oncology, The, 2016, 17, e471.	10.7	1
176	Is Li-Fraumeni syndrome really much more common?. Human Mutation, 2017, 38, 1619-1619.	2.5	1
177	Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study. Journal of Psychosocial Oncology Research and Practice, 2021, 3, e059.	0.5	1
178	Multidisciplinary Approach to Treatment: An Australian Perspective. , 2017, , 461-476.		1
179	Bone Sarcomas in the Adolescent and Young Adult Population. Pediatric Oncology, 2017, , 417-427.	0.5	1
180	Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians. Blood Advances, 2022, 6, 4593-4604.	5.2	1

#	Article	IF	Citations
181	Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results.. Health Psychology, 2022, 41, 396-408.	1.6	1
182	Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. Supportive Care in Cancer, 2022, 30, 8201-8210.	2.2	1
183	Gene expression profiling of sarcomas. Pathology, 2006, 38, 101-102.	0.6	0
184	The hard and soft sides of cancer programming. BioEssays, 2010, 32, 837-838.	2.5	0
185	Distinguishing activity from progress. Lancet Oncology, The, 2015, 16, 1586-1588.	10.7	0
186	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Personalized Medicine, 2018, 15, 13-24.	1.5	0
187	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. Psycho-Oncology, 2021, 30, 1920-1929.	2.3	0
188	No-Man's Land: Between Paediatric and Adult Medical Oncology. , 2009, , 885-906.		0